01 1Diprosone
02 3Diprospan
03 5Dovobet
Main Therapeutic Indication : Dermatology
Currency : USD
2020 Revenue in Millions : 65
2019 Revenue in Millions : 65
Growth (%) : 1
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 87
2020 Revenue in Millions : 83
Growth (%) : 5
Main Therapeutic Indication : Rheumatology
Currency : USD
2021 Revenue in Millions : 125
2020 Revenue in Millions : 118
Growth (%) : 6
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 61
2020 Revenue in Millions : 65
Growth (%) : 4
Main Therapeutic Indication : Dermatology
Currency : USD
2022 Revenue in Millions : 59
2021 Revenue in Millions : 61
Growth (%) : -3
Main Therapeutic Indication : Rheumatology
Currency : USD
2022 Revenue in Millions : 122
2021 Revenue in Millions : 125
Growth (%) : -2
Main Therapeutic Indication : Dermatology
Currency : USD
2023 Revenue in Millions : 53
2022 Revenue in Millions : 59
Growth (%) : 1
Main Therapeutic Indication : Rheumatology
Currency : USD
2023 Revenue in Millions : 91
2022 Revenue in Millions : 122
Growth (%) : -25
Main Therapeutic Indication : Dermatology
Currency : USD
2019 Revenue in Millions : 63
2018 Revenue in Millions : 55
Growth (%) : 15
LOOKING FOR A SUPPLIER?